ES8601694A1 - Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrina - Google Patents
Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrinaInfo
- Publication number
- ES8601694A1 ES8601694A1 ES535135A ES535135A ES8601694A1 ES 8601694 A1 ES8601694 A1 ES 8601694A1 ES 535135 A ES535135 A ES 535135A ES 535135 A ES535135 A ES 535135A ES 8601694 A1 ES8601694 A1 ES 8601694A1
- Authority
- ES
- Spain
- Prior art keywords
- thiazolin
- phenylimino
- chloro
- dimethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
PROCEDIMIENTO PARA PREPARAR UN COMPUESTO DE INCLUSION A BASE DE N,N-DIMETIL-2-CLORO-5-3-METIL-2-(FENILIMINO)-4-TIAZOLIN-4-IL-FENILSULFONAMIDA Y BETA-CICLODEXTRINA. COMPRENDE: A) HACER REACCIONAR BETA-CICLODEXTRINA Y N,N-METIL-2-CLORO-5-3-METIL-2-(FENILIMINA)-4-TIAZOLIN-4-IL-FENILSULFONAMIDA, CON CALENTAMIENTO HASTA LA TEMPERATURA DE EBULLICION Y EN SOLUCION ACIDA DE ACIDO CLORHIDRICO EN RELACION MOLAR DE 2 A 1 RESPECTIVAMENTE; B) ENFRIAR PARA PRECIPITAR EL COMPUESTO DE INCLUSION; Y C) SEPARAR POR FILTRACION, PARA OBTENER EL COMPUESTO DE INCLUSION A BASE DE N,N-DIMETIL-2-CLORO-5-3-METIL-2-(FENILIMINO)-4-TIAZOLIN-4-IL-FENILSULFONAMIDA Y BETA-CICLODEXTRINA. SE UTILIZA COMO SUSTITUTIVO DE HCG 497, DEBIDO A SU MAYOR HIDROSOLUBILIDAD, PARA PRODUCIR EFECTOS POLIPEDEMICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19833329517 DE3329517A1 (de) | 1983-08-16 | 1983-08-16 | Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate |
Publications (2)
Publication Number | Publication Date |
---|---|
ES8601694A1 true ES8601694A1 (es) | 1985-11-16 |
ES535135A0 ES535135A0 (es) | 1985-11-16 |
Family
ID=6206641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES535135A Granted ES535135A0 (es) | 1983-08-16 | 1984-08-14 | Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrina |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0141076A1 (es) |
JP (1) | JPS6058969A (es) |
KR (1) | KR850001737A (es) |
AU (1) | AU3196184A (es) |
DE (1) | DE3329517A1 (es) |
DK (1) | DK392384A (es) |
ES (1) | ES535135A0 (es) |
GR (1) | GR80116B (es) |
PT (1) | PT79080B (es) |
ZA (1) | ZA846327B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6081166A (ja) * | 1983-10-11 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法 |
JPH08777B2 (ja) * | 1985-04-08 | 1996-01-10 | 武田薬品工業株式会社 | 経口用抗菌固型組成物 |
SI8810082A8 (en) * | 1988-01-18 | 1995-12-31 | Lek Tovarna Farmacevtskih | Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine |
KR100503200B1 (ko) * | 2000-09-05 | 2005-07-25 | 주식회사 포스코 | 석탄 건조설비의 석탄 불출량 제어장치 |
-
1983
- 1983-08-16 DE DE19833329517 patent/DE3329517A1/de not_active Withdrawn
-
1984
- 1984-08-08 EP EP84109377A patent/EP0141076A1/de not_active Withdrawn
- 1984-08-14 KR KR1019840004894A patent/KR850001737A/ko not_active Application Discontinuation
- 1984-08-14 PT PT79080A patent/PT79080B/pt unknown
- 1984-08-14 ES ES535135A patent/ES535135A0/es active Granted
- 1984-08-14 GR GR80116A patent/GR80116B/el unknown
- 1984-08-15 ZA ZA846327A patent/ZA846327B/xx unknown
- 1984-08-15 AU AU31961/84A patent/AU3196184A/en not_active Abandoned
- 1984-08-15 DK DK392384A patent/DK392384A/da not_active Application Discontinuation
- 1984-08-15 JP JP59169454A patent/JPS6058969A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPS6058969A (ja) | 1985-04-05 |
DK392384D0 (da) | 1984-08-15 |
KR850001737A (ko) | 1985-04-01 |
DK392384A (da) | 1985-02-17 |
AU3196184A (en) | 1985-02-21 |
GR80116B (en) | 1984-12-14 |
ZA846327B (en) | 1985-03-27 |
EP0141076A1 (de) | 1985-05-15 |
DE3329517A1 (de) | 1985-02-28 |
ES535135A0 (es) | 1985-11-16 |
PT79080B (de) | 1986-09-08 |
PT79080A (de) | 1984-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0337256A3 (de) | Verfahren zur Herstellung pharmazeutischer Mischungen | |
AU1055083A (en) | 6-substituted-s-triazolo(3,4-alpha)phthalazine derivatives | |
HUT44779A (en) | Process for producing imidazole derivatives and pharmaceutical preparations comprising the same | |
HU913776D0 (en) | Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents | |
ZA842710B (en) | 20-spiroxanes and analogues having an open ring e,processes for their manufacture,and pharmaceutical preparations thereof | |
GR3005035T3 (es) | ||
HU9201937D0 (en) | Aryl ethers, process for their production, and for the production of medical preparations containing them as active agents | |
HU913216D0 (en) | Process for the production of saturated hydroxy-alkyl-kinoline acids, and of medical preparations containing them | |
HU895595D0 (en) | Diagnostical preparations and process for the production of chelates | |
EP0141300A3 (en) | An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof | |
HU910929D0 (en) | Process for the production of 2,8-dioxa-bicyclo/3,2,1/octane derivatives and medical preparations containing them | |
AU562216B2 (en) | Coated pharmaceutical preparations | |
DE3464333D1 (en) | Use of a salt of the acid n-acetyl (alpha, beta) aspartylglutamic for the manufacture of a drug having an anti-allergic activity for local administration | |
AU8117387A (en) | Inclusion complex of ibuproxam with beta-cyclodextrin, a process for preparing the same and a pharmaceutical preparation containing the same | |
AU2861389A (en) | Disubstituted pyridines | |
AU2687188A (en) | New derivatives of cyclic amino acids, a process for the preparation thereof, agents containing them, and the use thereof | |
ES8601694A1 (es) | Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrina | |
AU1004588A (en) | Solution ibuprofen complexes, compositions and processes for preparing same | |
AU2464384A (en) | Pharmaceutical iodophor preparations | |
HU9201358D0 (en) | 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents | |
AU6214086A (en) | Monoclonal antibodies against tumour-associated glycoproteins, a process for their preparation and their use | |
AU7481487A (en) | Novel complexes, process for their preparation, and medicinal use of them | |
AU2817589A (en) | Amino anthracenediones-bis platinum complexes, useful as antitumoral agents | |
HU913573D0 (en) | Complexes containing s(+)alkaneacids and alpha-hydroxy-alkaneacids | |
HU913345D0 (en) | Process for the production of benzopirane derivatives with effect on hypertension and vasodilatation, and medical preparations containing them |